Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

This trial evaluated the efficacy and safety of Johnson & Johnson’s (J&J) Akeega, which includes Zejula (niraparib), a highly ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

In the last few years, large Phase III trials showed improvements in survival and outcomes and led to the approval of a CYP17 inhibitor (abiraterone), an androgen receptor antagonist (enzalutamide ...

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), protein expression of protein expression of cytochrome P450 17A1 (CYP17), gene expression of CYP17, protein expression of androgen ...

Overall survival following enzalutamide resistance in metastatic castration-sensitive versus metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of ...